| Literature DB >> 19714295 |
Anikó Bohács1, Eva Pállinger, Lilla Tamási, János Rigó, Zsolt Komlósi, Veronika Müller, Yang Dong, Pál Magyar, András Falus, György Losonczy.
Abstract
PROBLEM: Pregnancy-associated immunologic alterations may improve the course of asthma. Severe maternal asthma with an exacerbation impairs fetal growth. METHOD OF STUDY: Lymphocyte activation was estimated by flow cytometry analysis of surface markers in non-pregnant healthy and mild or moderate persistent asthmatic women and healthy as well as mild or moderate persistent asthmatic, third trimester pregnant women.Entities:
Mesh:
Substances:
Year: 2010 PMID: 19714295 PMCID: PMC2803259 DOI: 10.1007/s00011-009-0070-2
Source DB: PubMed Journal: Inflamm Res ISSN: 1023-3830 Impact factor: 4.575
Characterization of circulating lymphocyte subpopulations by immunophenotyping
| FITC | Pe | PerCP or Cy-chrome | APC |
|---|---|---|---|
| Isotype control Ab | Isotype control Ab | Isotype control Ab | Isotype control Ab |
| CD25 | CD8 | CD4 | CD3 |
| CD71 | CD152 | CD19 | CD3 |
| CD56 | HLA-DR | CD16 | CD3 |
| CD45 | CD14 | ||
| CD28 | CD54 | CD4 | CD11b |
| CD28 | CD54 | CD8 | CD11b |
Age and obstetrical data of subjects (means ± SEM)
| Healthy non-pregnant | Asthmatic non-pregnant | Healthy pregnant | Asthmatic pregnant | |
|---|---|---|---|---|
| Number | 10 | 12 | 13 | 21 |
| Age (year) | 29.0 ± 1.6 | 31.4 ± 1.7ns | 29.6 ± 1.1ns | 31.7 ± 1.0ns |
| BMI (kg/m2) | 20.6 ± 0.44 | 25.02 ± 1.45a | 24.77 ± 0.55a | 26.0 ± 1.1a,ns |
| Gestational age (week) at examination | – | – | 26.8 ± 2.0 | 26.4 ± 1.7ns |
| At delivery | – | – | 39.1 ± 0.3 | 38.9 ± 0.3ns |
| Mean birth weight (g) | – | – | 3,332 ± 93.1 | 3,224 ± 145.5b |
| Sex of newborns (female/male) | – | – | 5/8 | 8/13 |
BMI body mass index
a p < 0.05 vs. the healthy non-pregnant group
b p < 0.05 vs. the healthy pregnant group, ns not significant vs. the appropriate healthy group
Clinical data of asthmatic patients (non-pregnant and pregnant; means ± SEM, where appropriate)
| Asthmatic non-pregnant (12) | Asthmatic pregnant (21) | |
|---|---|---|
| Distribution of asthma severity (GINA II/III) | 8/4 | 17/6ns |
| PEF (% of predicted) | 72.08 ± 5.41* | 72.5 ± 3.16* |
| FEV1 (% of predicted) | 86.00 ± 5.59 | 87.62 ± 3.24 |
|
| 0.34 ± 0.06$ | 0.27 ± 0.03$ |
| pO2 (mmHg) | 84.03 ± 3.4* | 88.35 ± 2.12* |
| pCO2 (mmHg) | 35.47 ± 0.75* | 30.93 ± 0.49*,¶ |
| pH | 7.52 ± 0.01$ | 7.51 ± 0.01$ |
| Number of patients on inhaled corticosteroid (ICS) | 9 | 11ns |
| Number of patients on inhaled long-acting β2-agonist (LABA) | 4 | 4ns |
| Daily dose of inhaled short-acting β2-agonist (puffs) | 2 (0, 4)a | 2 (0, 4)a |
| Daily dose of inhaled formoterol (μg) | 11.25 | 10.13ns |
| Daily dose of inhaled corticosteroid (beclomethasone equivalent μg) | 587 ± 74 | 781 ± 120ns |
GINA global initiative for asthma, PEF peak expiratory flow; Raw-airway resistance; pO partial pressure of oxygen in arterialized capillary blood; pCO partial pressure of carbon-dioxide in arterialized capillary blood; FEV1-forced expiratory volume in one-second, ns non significant vs. non-pregnant astmatics; *less or $more than the healthy age matched population mean ± 2 × SD; ¶significant (p < 0.001) vs. asthmatic non-pregnant
aMedian, smallest, largest. No significant differences among the two asthmatic groups except for pCO2
Major lymphocyte sub-populations in peripheral blood of non-pregnant healthy and asthmatic subjects, and healthy and asthmatic pregnants (total numbers of cells/μl blood, means ± SEM)
| Lymphocyte subset | Immuno-phenotype | Healthy non-pregnant ( | Asthmatic non-pregnant ( | Healthy pregnant ( | Asthmatic pregnant ( |
|---|---|---|---|---|---|
| T cells | CD3+ | 1,325 ± 118.1 | 1,586 ± 134.8 | 1,405 ± 60.3 | 1,256 ± 61.9¶ |
| T-helper cells | CD3+CD4+ | 777.2 ± 92.4 | 947.3 ± 94.4 | 764.7 ± 35.0 | 771.9 ± 42.1 |
| T-cytotoxic cells | CD3+CD8+ | 453.1 ± 43.3 | 554.9 ± 62.6 | 557.8 ± 39.1 | 435.3 ± 28.0 |
| NK T cells | CD3+CD16+CD56+ | 117.5 ± 19.1 | 238.1 ± 27.0** | 200.6 ± 20.4* | 178.2 ± 16.2 |
| B cells | CD19+ | 128.6 ± 10.5 | 183.1 ± 22.9 | 163.1 ± 13.3 | 174.3 ± 14.4 |
| NK cells | CD3−CD16+CD56+ | 256.2 ± 56.1 | 296.1 ± 73.9 | 233.1 ± 49.1 | 300.8 ± 45.1 |
Statistical analysis: ANOVA and Newman–Keuls comparison post-hoc test were applied if possible. ¶ p < 0.05 vs. asthmatic non-pregnant; *p < 0.05; **p < 0.01 vs. healthy non-pregnant
Distribution of activated lymphocyte sub-populations in peripheral blood of non-pregnant healthy and asthmatic subjects and healthy, or asthmatic pregnants (total numbers of cells/μl blood; means ± SEM)
| Immuno-phenotype | Healthy non-pregnant ( | Asthmatic non-pregnant ( | Healthy pregnant ( | Asthmatic pregnant ( |
|---|---|---|---|---|
| CD3+CD25+ | 155.0 ± 23.6 | 288.8 ± 29.1** | 240.4 ± 19.3* | 244.7 ± 23.3 |
| CD3+CD95+ | 344.5 ± 39.3 | 708.7 ± 72.5** | 573.7 ± 72.8* | 580.5 ± 54.7 |
| CD3+HLADR+ | 26.77 ± 6.8 | 33.11 ± 6.5 | 35.56 ± 7.7 | 23.43 ± 2.2 |
| CD4+CD25+ | 126.1 ± 20.3 | 245.0 ± 27.6* | 207.2 ± 16.3* | 222.0 ± 22.3 |
| CD4+CD28+ | 619.94 ± 109.2 | 972.9 ± 120.7* | 736.0 ± 30.3 | 703.6 ± 45.9 |
| CD4+CD54+ | 73.9 ± 13.9 | 193.1 ± 32.8* | 126.2 ± 18.3 | 192.6 ± 26.8 |
| CD4+CD11b+ | 28.5 ± 5.2 | 53.58 ± 13.3 | 91.78 ± 20.9* | 51.57 ± 10.9 |
| CD8+CD25+ | 22.7 ± 3.6 | 45.08 ± 8.4 | 35.44 ± 9.3 | 30.10 ± 4.2 |
| CD8+CD28+ | 295.7 ± 34.9 | 368.7 ± 41.0 | 345.7 ± 26.8 | 282.8 ± 20.5 |
| CD8+CD54+ | 74.02 ± 13.87 | 193.2 ± 32.8* | 278.6 ± 28.9** | 274.2 ± 30.8 |
| CD8+CD11b+ | 116.1 ± 15.2 | 215.2 ± 25.2* | 249.2 ± 36.0* | 220.0 ± 22.8 |
| CD19+CD71+ | 44.2 ± 6.9 | 100.5 ± 22.1* | 105.6 ± 12.9* | 55.0 ± 9.0$ |
*p < 0.05; **p < 0.01 vs. healthy non-pregnants; $ p < 0.05 vs. healthy pregnants